Select patients with breast cancer who experience pathologic complete response to neoadjuvant systemic therapy and undergo radiotherapy may be able to forego breast surgery, according to study results ...

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can ...

The Incucyte ® Live-Cell Analysis System is a fully automated platform for phase contrast and two-color fluorescence imaging, ...

Ingelheim, Germany Wednesday, April 30, 2025, 14:00 Hrs [IST] ...

The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...